2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Gamida Cell ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies omidubicel - Hematological Malignancies | Phase 3 | Completed | Gamida Cell ltd | 36 | 2020-07-08 | 2026-06-22 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS NiCord® (omidubicel), Cord Blood Unit - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Gamida Cell ltd | 125 | 2016-12-16 | 2026-02-25 |
Hematologic Neoplasms (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
United States (2) · Brazil (1) · France (1) · Israel (1) · Italy (1) · Netherlands (1) · Portugal (1) · Singapore (1) · Spain (1) · United Kingdom (1)